WO2009025159A1 - 統合失調症の検査および治療 - Google Patents

統合失調症の検査および治療 Download PDF

Info

Publication number
WO2009025159A1
WO2009025159A1 PCT/JP2008/063803 JP2008063803W WO2009025159A1 WO 2009025159 A1 WO2009025159 A1 WO 2009025159A1 JP 2008063803 W JP2008063803 W JP 2008063803W WO 2009025159 A1 WO2009025159 A1 WO 2009025159A1
Authority
WO
WIPO (PCT)
Prior art keywords
schizophrenia
disclosed
detection
treatment
glyoxalase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/063803
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
Masanari Itokawa
Toshio Miyata
Makoto Arai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical and Biological Laboratories Co Ltd
Tokyo Metropolitan Organization for Medical Research
RenaScience Co Ltd
Tokai University Educational System
Original Assignee
Medical and Biological Laboratories Co Ltd
Tokyo Metropolitan Organization for Medical Research
RenaScience Co Ltd
Tokai University Educational System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical and Biological Laboratories Co Ltd, Tokyo Metropolitan Organization for Medical Research, RenaScience Co Ltd, Tokai University Educational System filed Critical Medical and Biological Laboratories Co Ltd
Priority to EP08792016.1A priority Critical patent/EP2189537B1/en
Priority to SI200831305T priority patent/SI2189537T1/sl
Priority to ES08792016.1T priority patent/ES2515168T3/es
Priority to HRP20140993AT priority patent/HRP20140993T1/hr
Priority to US12/674,018 priority patent/US8809329B2/en
Priority to DK08792016.1T priority patent/DK2189537T3/da
Priority to PL08792016T priority patent/PL2189537T3/pl
Publication of WO2009025159A1 publication Critical patent/WO2009025159A1/ja
Anticipated expiration legal-status Critical
Priority to US14/325,808 priority patent/US20140335517A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/JP2008/063803 2007-08-20 2008-07-31 統合失調症の検査および治療 Ceased WO2009025159A1 (ja)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP08792016.1A EP2189537B1 (en) 2007-08-20 2008-07-31 Detection and treatment of schizophrenia
SI200831305T SI2189537T1 (sl) 2007-08-20 2008-07-31 Detekcija in zdravljenje shizofrenije
ES08792016.1T ES2515168T3 (es) 2007-08-20 2008-07-31 Detección y tratamiento de la esquizofrenia
HRP20140993AT HRP20140993T1 (hr) 2007-08-20 2008-07-31 Otkrivanje i lijeäśenje shizofrenije
US12/674,018 US8809329B2 (en) 2007-08-20 2008-07-31 Detection and treatment of schizophrenia
DK08792016.1T DK2189537T3 (da) 2007-08-20 2008-07-31 Detektion og behandling af skizofreni
PL08792016T PL2189537T3 (pl) 2007-08-20 2008-07-31 Wykrywanie i leczenie schizofrenii
US14/325,808 US20140335517A1 (en) 2007-08-20 2014-07-08 Detection and treatment of schizophrenia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-214047 2007-08-20
JP2007214047A JP5288365B2 (ja) 2007-07-17 2007-08-20 統合失調症の検査および治療

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/674,018 A-371-Of-International US8809329B2 (en) 2007-08-20 2008-07-31 Detection and treatment of schizophrenia
US14/325,808 Division US20140335517A1 (en) 2007-08-20 2014-07-08 Detection and treatment of schizophrenia

Publications (1)

Publication Number Publication Date
WO2009025159A1 true WO2009025159A1 (ja) 2009-02-26

Family

ID=40378067

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/063803 Ceased WO2009025159A1 (ja) 2007-08-20 2008-07-31 統合失調症の検査および治療

Country Status (11)

Country Link
US (2) US8809329B2 (https=)
EP (2) EP2662453A3 (https=)
JP (1) JP5288365B2 (https=)
CY (1) CY1115640T1 (https=)
DK (1) DK2189537T3 (https=)
ES (1) ES2515168T3 (https=)
HR (1) HRP20140993T1 (https=)
PL (1) PL2189537T3 (https=)
PT (1) PT2189537E (https=)
SI (1) SI2189537T1 (https=)
WO (1) WO2009025159A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010143762A1 (ko) * 2009-06-12 2010-12-16 (주)바이오니아 리보핵산 분해효소 활성억제용 화합물 및 이를 포함하는 핵산 보관용 용기

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011142460A1 (ja) * 2010-05-14 2011-11-17 財団法人東京都医学総合研究所 統合失調症の検出方法
CN102993191B (zh) * 2012-12-18 2015-05-27 苏州大学 一种含有吖内酯与吡唑啉酮的杂环手性化合物及其衍生物、合成方法及用途
US20170258791A1 (en) 2014-08-29 2017-09-14 Project Pm Co., Ltd. Pharmaceutical composition formed by combining pyridoxamine compound and thiamine compound
KR101796391B1 (ko) * 2015-07-24 2017-11-09 동국대학교 산학협력단 Blt 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 조성물
JP6105111B1 (ja) 2016-03-02 2017-03-29 国立大学法人東北大学 自閉スペクトラム症改善用組成物
JP6924964B2 (ja) * 2017-07-07 2021-08-25 パナソニックＩｐマネジメント株式会社 情報提供方法、情報処理システム、情報端末、及び情報処理方法
CN110022769B (zh) * 2017-07-07 2022-09-27 松下知识产权经营株式会社 信息提供方法、信息处理系统、信息终端及信息处理方法
KR20200024744A (ko) * 2017-07-07 2020-03-09 파나소닉 아이피 매니지먼트 가부시키가이샤 정보 제공 방법, 정보 처리 시스템, 정보 단말, 및 정보 처리 방법
WO2019168062A1 (ja) 2018-02-27 2019-09-06 キッコーマン株式会社 新規酵素及びそれを用いたペントシジンの測定方法
US20220396822A1 (en) * 2019-08-27 2022-12-15 Kikkoman Corporation Method for Measuring Pentosidine and Measurement Kit

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001245661A (ja) 2000-03-07 2001-09-11 Univ Niigata 遺伝子発現を指標とする精神分裂病の客観的診断法
JP2003038198A (ja) 2001-07-27 2003-02-12 Univ Niigata 精神分裂病により発現量が変化する遺伝子を規定する核酸を解析する方法
JP2003212795A (ja) 2002-01-15 2003-07-30 Japan Science & Technology Corp 精神分裂病の診断薬
WO2004005935A1 (ja) 2002-07-04 2004-01-15 Mitsubishi Pharma Corporation 統合失調症の検査、診断方法
JP2004251865A (ja) 2003-02-19 2004-09-09 Takashi Muramatsu 統合失調症およびアルツハイマー病の検査薬
JP2005055227A (ja) 2003-07-31 2005-03-03 Japan Science & Technology Agency 統合失調症の診断方法
WO2005030737A1 (ja) 2003-09-30 2005-04-07 Sankyo Company, Limited テトラゾール環又はチアゾリジンジオン環を有するフェニレン誘導体
WO2005054205A1 (ja) 2003-12-05 2005-06-16 Tokai University Educational System 蛋白修飾物生成抑制剤
JP2005278490A (ja) 2004-03-29 2005-10-13 Japan Science & Technology Agency 統合失調症に関与する生物学的マーカーの判定方法およびその利用
WO2007026962A1 (ja) 2005-08-31 2007-03-08 Daiichi Sankyo Company, Limited フェニレン誘導体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52102431A (en) 1976-02-25 1977-08-27 Kyowa Hakko Kogyo Co Ltd Remedies for mental disorder
CA2436522A1 (en) 2001-01-31 2002-08-08 Katia Vancompernolle Phosphorylated glyoxalase i and its use
NL1019368C2 (nl) * 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US20050249823A1 (en) * 2003-11-04 2005-11-10 Murphy Tanya K Methods for the prevention or amelioration of neuropsychiatric and related diseases
US20100137635A1 (en) * 2005-06-07 2010-06-03 Inbiotex Inc. Radical scavenger and active oxygen eliminating agent

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001245661A (ja) 2000-03-07 2001-09-11 Univ Niigata 遺伝子発現を指標とする精神分裂病の客観的診断法
JP2003038198A (ja) 2001-07-27 2003-02-12 Univ Niigata 精神分裂病により発現量が変化する遺伝子を規定する核酸を解析する方法
JP2003212795A (ja) 2002-01-15 2003-07-30 Japan Science & Technology Corp 精神分裂病の診断薬
WO2004005935A1 (ja) 2002-07-04 2004-01-15 Mitsubishi Pharma Corporation 統合失調症の検査、診断方法
JP2004251865A (ja) 2003-02-19 2004-09-09 Takashi Muramatsu 統合失調症およびアルツハイマー病の検査薬
JP2005055227A (ja) 2003-07-31 2005-03-03 Japan Science & Technology Agency 統合失調症の診断方法
WO2005030737A1 (ja) 2003-09-30 2005-04-07 Sankyo Company, Limited テトラゾール環又はチアゾリジンジオン環を有するフェニレン誘導体
WO2005054205A1 (ja) 2003-12-05 2005-06-16 Tokai University Educational System 蛋白修飾物生成抑制剤
JP2005278490A (ja) 2004-03-29 2005-10-13 Japan Science & Technology Agency 統合失調症に関与する生物学的マーカーの判定方法およびその利用
WO2007026962A1 (ja) 2005-08-31 2007-03-08 Daiichi Sankyo Company, Limited フェニレン誘導体

Non-Patent Citations (46)

* Cited by examiner, † Cited by third party
Title
"Diagnostic and Statistical Manual, Fourth Edition", AMERICAN PSYCHIATRIC ASSOCIATION
"Polymerase Chain Reaction-Single Strand Conformation Polymorphism Analysis", BIOTECHNIQUES, vol. 16, 1994, pages 296 - 297
ANAL. CHEM., vol. 72, 2000, pages 1334 - 1341
BIOTECHNIQUES, vol. 11, 1991, pages 246 - 249
BIOTECHNIQUES, vol. 21, 1996, pages 216 - 218
BIOTECHNIQUES, vol. 21, 1996, pages 510 - 514
BIOTECHNIQUES, vol. 27, 1999, pages 1016 - 1018
BRUCE ET AL.: "Geneme Analysis/A Laboratory Manual", vol. 4, 1999, COLD SPRING HARBOR LABORATORY
CLIN. CHIM. ACTA, vol. 189, 1990, pages 153 - 157
DNA CELL. BIOL., vol. 14, 1995, pages 87 - 94
EUR. J. CLIN. CHEM. CLIN. BIOCHEM., vol. 35, 1997, pages 545 - 548
GALE C.P. ET AL.: "Common polymorphisms in the glyoxalase-1 gene and their association with pro-thrombotic factors", DIAB.VASC.DIS.RES., vol. 1, no. 1, 2004, pages 34 - 39, XP008132143 *
GENE & MEDICINE, vol. 4, 2000, pages 46 - 48
GENE & MEDICINE, vol. 4, 2000, pages 47 - 48
GENE & MEDICINE, vol. 4, 2000, pages 50 - 51
GENET. ANAL., vol. 14, 1999, pages 143 - 149
GENOME RES., vol. 7, 1997, pages 378 - 388
GENOME RES., vol. 8, 1998, pages 549 - 556
J. CLIN. MICROBIOL., vol. 34, 1996, pages 2933 - 2936
J.BIOL.CHEM., vol. 30, 1999, pages 21387 - 21394
KENICHI MATSUBARA; YOSHIKI SAKAKI: "Strategy for SNP genetic polymorphism", NALAYAMA-SHOTEN, pages: 128 - 135
LIVAK KJ, GENE ANAL, vol. 14, 1999, pages 143
LYAMICHEV V. ET AL., NAT BIOTECHNOL, vol. 17, 1999, pages 292
MCGLASHAN, SCHIZOPHR BULL, 1988
MCLELLAN AC: "Thornalley PJ: Glyoxalase activity in human red blood cells fractioned by age", MECH AGEING DEV, vol. 48, 1989, pages 63 - 71
MCLELLAN AC; THORNALLEY PJ: "Glyoxalase activity in human red blood cells fractioned by age", MECH AGEING DEV, vol. 48, 1989, pages 63 - 71
MIYATA T. ET AL.: "Glyoxalase I deficiency is associated with an unusual level of advanced glycation end products in a hemodialysis patient", KIDNEY INT., vol. 60, no. 6, 2001, pages 2351 - 2359, XP002355559 *
MIYATA, T ET AL., J. AM. SOC., NEPHROL., vol. 7, 1996, pages 1198 - 1206
MIYATA, T. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 2353 - 2358
MIYATA, T. ET AL., PROC. NATL. ACAD. SCI., USA, vol. 93, 1996, pages 2353 - 2358
MORRIS T ET AL., J CLIN MICROBIOL, vol. 34, 1996, pages 2933
NAT. BIOTECHNOL., vol. 1, 1998, pages 49 - 53
NAT. BIOTECHNOL., vol. 1, 1999, pages 87 - 88
NAT. BIOTECHNOL., vol. 17, 1999, pages 292 - 296
NAT. GENET., vol. 3, 1998, pages 225 - 232
NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 303 - 308
NUC. ACIDS. RES., vol. 19, 1991, pages 3561 - 3567
NUC. ACIDS. RES., vol. 20, 1992, pages 4831 - 4837
POLITI P. ET AL.: "Association analysis of the functional Ala111Glu polymorphism of the glyoxalase I gene in panic disorder", NEUROSCI.LETT., vol. 396, no. 2, 2006, pages 163 - 166, XP025023590 *
PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 10756 - 10761
SACCO R. ET AL.: "Case-control and family-based association studies of candidate genes in autistic disorder and its endophenotypes: TPH2 and GLO1", BMC MED.GENET., vol. 8, no. 11, March 2007 (2007-03-01), pages 1 - 9, XP008132135 *
SAMBROOK ET AL.: "Molecular Cloning", 1989, COLD SPRING HARBOUR LABORATORY PRESS
SAMBROOK J. ET AL.: "Molecular Cloning: A Laboratory Manual", COLD SPRING HARBOR LABORATORY
SCIENCE, vol. 5109, 1993, pages 778 - 783
See also references of EP2189537A4
TURNER W.J. ET AL.: "Genetic markers for schizotaxia", BIOL.PSYCHIATRY, vol. 14, no. 1, 1979, pages 177 - 206, XP008132140 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010143762A1 (ko) * 2009-06-12 2010-12-16 (주)바이오니아 리보핵산 분해효소 활성억제용 화합물 및 이를 포함하는 핵산 보관용 용기
US8551426B2 (en) 2009-06-12 2013-10-08 Bioneer Corporation Compound for inhibiting activity of ribonuclease, and container for storing nucleic acid containing the same

Also Published As

Publication number Publication date
EP2189537A1 (en) 2010-05-26
US20110028470A1 (en) 2011-02-03
EP2189537B1 (en) 2014-10-08
US20120065198A2 (en) 2012-03-15
EP2662453A2 (en) 2013-11-13
CY1115640T1 (el) 2017-01-04
PT2189537E (pt) 2014-10-30
JP2009039088A (ja) 2009-02-26
HRP20140993T1 (hr) 2014-12-19
US8809329B2 (en) 2014-08-19
EP2189537A4 (en) 2010-08-11
SI2189537T1 (sl) 2014-11-28
ES2515168T3 (es) 2014-10-29
PL2189537T3 (pl) 2015-01-30
DK2189537T3 (da) 2014-10-27
EP2662453A3 (en) 2014-02-26
JP5288365B2 (ja) 2013-09-11
US20140335517A1 (en) 2014-11-13

Similar Documents

Publication Publication Date Title
WO2009025159A1 (ja) 統合失調症の検査および治療
WO2009048072A1 (ja) 破骨細胞関連蛋白質Ｓｉｇｌｅｃ－１５を標的とした抗体
WO2008062276A3 (en) Acetylene derivatives as stearoyl coa desaturase inhibitors
WO2007100880A8 (en) Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
WO2010020475A3 (de) Verfahren zur verbesserung der reinigungsleistung eines wasch- oder reinigungsmittels
WO2009100872A8 (en) Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
NO20055892L (no) Karboksylsyrederivater
MX2008014101A (es) Acidos carboxilicos sustituidos con 4,5-difenil-pirimidinilamino, metodo para su produccion y su uso como medicamentos.
WO2010001169A3 (en) Chemical compounds 251
WO2005092877A8 (de) Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2007136762A3 (en) Production of fatty acids and derivatives thereof
WO2002086107A3 (en) A method for differentiating stem cells into insulin-producing cells
WO2009129465A3 (en) Compositions and methods for inhibiting expression of xbp-1 gene
WO2008024139A3 (en) Inhibitors of fatty acid amide hydrolase
WO2007140005A3 (en) Oxazolyl piperidine modulators of fatty acid amide hydrolase
WO2007103370A3 (en) Quinazoline derivatives as phosphodiesterase 10 inhibitors
WO2007095584A3 (en) Histone Deacetylase Inhibitors
WO2008027162A3 (en) 129xe biosensors and their use
WO2008106594A3 (en) Inhibitors of nucleophosmin (npm) and methods for inducing apoptosis
Yan et al. Exploring an efficient and eco-friendly signaling molecule and its quorum quenching ability for controlling Microcystis blooms
WO2007085531A3 (de) Geruchsverhindernde wasserabsorbierende zusammensetzungen enthaltend urease-inhibitoren
MX2008011175A (es) Inhibidores de fosfodiesterasa 10.
UA86441C2 (ru) (2-гидроксиэтил)триметиламмония тиоктат (холина тиоктат), имеющий гепатопротекторное, гипоаммониемическое и детоксицирующее действие, способ его получения, фармацевтическая композиция на его основе
NO20081681L (no) N-[1,3,4]-tiadiazol-2-yl-benzensulfonamider, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytika
WO2010019914A3 (en) Anti-arrhythmia agents, methods of their use, methods for their identification, and kits thereofre

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08792016

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12674018

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008792016

Country of ref document: EP